What is JBSS's health score?

SANFILIPPO JOHN B & SON INC (JBSS) has a TradeApes health score of 59 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is JBSS's estimated fair value?

Based on our 5-year discounted cash flow model, SANFILIPPO JOHN B & SON INC's estimated fair value is $86.33 per share, representing a 15.3% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is JBSS undervalued or overvalued?

Our model currently rates JBSS as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for JBSS... Refresh in a moment for the full analysis.

SANFILIPPO JOHN B & SON INC (JBSS)

Consumer Defensive Fair Value low mixed

$74.91

Updated: 2026-05-30

TradeApes Score

Financial Strength

60 Healthy

Operating Trend

55 Mixed

Relative Value

60 Healthy

Capital Allocation

45 Mixed

Risk

80 Strong

Est. Fair Value $86.33

DCF Upside +15.3%

Sector Rank #207 of 865

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Low FCF yield — below 1%, price implies exceptional future growth

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.